You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/68399
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSpolidório, Luis Carlos-
dc.contributor.authorHolzhausen, Marinella-
dc.contributor.authorPalomari Spolidorio, Denise M.-
dc.contributor.authorNassar, Carlos A.-
dc.contributor.authorNassar, Patricia O.-
dc.contributor.authorMuscará, Marcelo Nicolás-
dc.date.accessioned2014-05-27T11:21:37Z-
dc.date.accessioned2016-10-25T18:21:06Z-
dc.date.available2014-05-27T11:21:37Z-
dc.date.available2016-10-25T18:21:06Z-
dc.date.issued2005-09-01-
dc.identifierhttp://dx.doi.org/10.1902/jop.2005.76.9.1520-
dc.identifier.citationJournal of Periodontology, v. 76, n. 9, p. 1520-1525, 2005.-
dc.identifier.issn0022-3492-
dc.identifier.urihttp://hdl.handle.net/11449/68399-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/68399-
dc.description.abstractBackground: Cyclosporin (CsA) and tacrolimus (FK-506) are immunosuppressive drugs that specifically inhibit T-cell activation via calcineurin inhibition. Gingival overgrowth is a common side effect following the administration of CsA. The severity of gingival overgrowth seen in patients taking FK-506 is less than that observed with CsA. Little is known about the involvement of saliva in drug-induced gingival overgrowth. The purpose of this study was to investigate the salivary contents of tumor growth factor β1 (TGF-β1), epidermal growth factor (EGF), and interleukin-6 (IL-6) as well as the hystometry of gingival tissue obtained from rats treated with either FK-506 or CsA. Methods: For 30 or 60 days rats received daily subcutaneous injection doses of either CsA or FK-506 (10 mg/kg). The concentrations of TGF-β1, EGF, and IL-6 in saliva were determined by enzyme-linked immunosorbent assay, and after histological processing, the oral epithelium and connective tissue were assessed at the region of the lower first molars. Results: The levels of TGF-β1, EGF, and IL-6 in saliva were not significantly altered by any of the treatments after 30 days. After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-β1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506. Conclusion: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-β1, EGF, and IL-6.en
dc.format.extent1520-1525-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectAnimal studies-
dc.subjectCyclosporin A/adverse effects-
dc.subjectGingival hyperplasia/etiology-
dc.subjectGrowth factors, epidermal-
dc.subjectGrowth factors, tumor β1-
dc.subjectInterleukin-6-
dc.subjectSaliva/analysis-
dc.subjectTacrolimus/adverse effects-
dc.subjectcyclosporin-
dc.subjectcytokine-
dc.subjectepidermal growth factor-
dc.subjectinterleukin 6-
dc.subjecttacrolimus-
dc.subjecttransforming growth factor beta1-
dc.subjectanimal experiment-
dc.subjectanimal model-
dc.subjectanimal tissue-
dc.subjectconcentration response-
dc.subjectconnective tissue-
dc.subjectcontrolled study-
dc.subjectenzyme linked immunosorbent assay-
dc.subjectfibroblast-
dc.subjectgingiva overgrowth-
dc.subjecthistometry-
dc.subjectmale-
dc.subjectmolar tooth-
dc.subjectmouth mucosa-
dc.subjectnonhuman-
dc.subjectrat-
dc.subjectsalivation-
dc.subjectAnimals-
dc.subjectCyclosporine-
dc.subjectCytokines-
dc.subjectEpidermal Growth Factor-
dc.subjectGingival Overgrowth-
dc.subjectImmunosuppressive Agents-
dc.subjectMale-
dc.subjectRats-
dc.subjectRats, Sprague-Dawley-
dc.subjectSaliva-
dc.subjectTacrolimus-
dc.subjectTransforming Growth Factor beta-
dc.subjectTransforming Growth Factor beta1-
dc.titleCyclosporin but not tacrolimus significantly increases salivary cytokine contents in ratsen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationDepartment of Pathology Dental School of Araraquara State University of São Paulo (UNESP), Rua Hamaitá 1680, Araraquara, SP 14801-903-
dc.description.affiliationDepartment of Periodontology Dental School of Araraquara State University of São Paulo (UNESP), Rua Hamaitá 1680, São Paulo 14801-903-
dc.description.affiliationDepartment of Pharmacology Institute of Biomedical Sciences University of São Paulo, São Paulo, SP-
dc.description.affiliationUnespDepartment of Pathology Dental School of Araraquara State University of São Paulo (UNESP), Rua Hamaitá 1680, Araraquara, SP 14801-903-
dc.description.affiliationUnespDepartment of Periodontology Dental School of Araraquara State University of São Paulo (UNESP), Rua Hamaitá 1680, São Paulo 14801-903-
dc.identifier.doi10.1902/jop.2005.76.9.1520-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofJournal of Periodontology-
dc.identifier.scopus2-s2.0-26944464177-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.